Background
==========

Proliferation and dedifferentiation of HIV-1 infected renal epithelium is singularly unique compared to the effects of HIV-1 infection in other non-lymphoid tissues. Indeed, unlike the atrophy and cell-death of infected central nervous system \[[@B1]\], cardiac \[[@B2]\], or gastro-intestinal \[[@B3]\] parenchyma, aberrant cell-cycle progression of infected renal epithelium is a defining feature of HIV-associated nephropathy (HIVAN) \[[@B4],[@B5]\]. Yet, the mechanisms are largely unknown whereby HIV-1 subverts the cell-cycle controls that normally maintain renal epithelial in G~0~. Nonetheless, several observations from *in vitro* and *in vivo* models of HIVAN pathogenesis suggest that HIV-1 expression itself may be a key pathogenic factor. Infection of cultured podocytes with replication incompetent HIV-1 demonstrated that HIV-1 gene expression leads to the proliferation and dedifferentiation of the infected podocytes \[[@B6]-[@B8]\], recapitulating the phenotypes observed in HIVAN specimens \[[@B9],[@B10]\]. Similarly, renal expression of replication incompetent HIV-1 proviral transgenes in mice and rats produces a proliferative renal lesion that is indistiguisable both histopathologically and clinically from human HIVAN \[[@B11]-[@B14]\]. These observations raise the possibility that HIV-1 gene products may interact with mitogenic pathways in infected renal epithelium to cause aberrant cell-cycle engagement.

In comparison to the two general alternative mechanisms utilized by known transforming viruses to promote cell-cycle progression, namely, by activating or bypassing endogenous D-type cyclins (herein, referred to as \"cyclin D\"), it has not been established whether HIV-1 gene products trigger either cyclin D-dependent or cyclin D-independent proliferation in non-lymphoid tissues \[[@B15]\]. In infected renal epithelium, HIV-1 could disrupt the inhibitory binding of pRb to E2F independent of endogenous cyclin D, analogous to transforming viral mechanisms that bypass and down-regulate endogenous cyclin D, such as SV-40 T antigen binding to pRb \[[@B16]\], HHV-8 *v*-cyclin binding to and activating cyclin-dependent kinase-6 (CDK) \[[@B17]\], and activation of cyclin E by EBV-induced *c*-myc \[[@B18]\]. Alternatively, HIV-1 could activate cyclin D-dependent proliferation, as exemplified by RSV *v*-src-mediated signaling \[[@B19]\]. In most tissues, the selective activation of these cell-cycle pathways is readily discernable. Indeed, if cells depend on cyclin D-mediated G1 → S transition, passage from G~0~ through the restriction point in G~1~ is dependent on the *de novo* expression of cyclin D transcript, accumulation of nuclear cyclin D protein, and cyclin D/CDK-4/6 phosphorylation of pRb \[[@B20]\]. Then, although nuclear-localized cyclin D decreases in S phase in individual cells \[[@B21]\], total cyclin D in asynchronously proliferating cell populations remain elevated compared to quiescent cells \[[@B20]\]. In renal epithelial and mesenchymal cells, cyclin D~1~ is the dominant D-type cyclin activated during cell-cycle progression, both during nephrogenesis \[[@B22]\] and in non-viral-mediated kidney cell proliferation \[[@B23]\].

Here, we ask whether infected podocytes expressing HIV-1 genes show the hallmarks of cyclin D~1~-dependent proliferation, specifically the up-regulation of cyclin D~1~ transcript and protein expression and the subsequent phosphorylation of pRb on serine 780, a target site of active cyclin D~1~/CDK-4/6 that is not shared with cyclin E/CDK-2 complexes \[[@B24]\]. Utilizing two well-characterized models of HIVAN pathogenesis, HIV-1 transgenic mice \[[@B11]-[@B13]\] and HIV-1 infection of cultured podocytes \[[@B6]-[@B8]\] we find not only these hallmarks of cyclin D~1~-dependent proliferation, but also dysregulation of cyclin D~1~ expression that normally occurs with cell-cell contact and differentiation \[[@B25]\].

Results
=======

Phospho-pRb (Ser780) expression in vivo
---------------------------------------

Cyclin D~1~ is characterized as the major D-type cyclin controlling G~1~-phase progression in kidney cells, both during normal and abnormal proliferation \[[@B22],[@B23]\]. To determine whether cyclin D~1~ may be active in promoting G~1~ → S progression in kidneys expressing HIV-1 genes, we utilized a well-characterized HIV-1 transgenic mouse model (Tg26) of HIVAN \[[@B11]-[@B13]\]. Secondary to renal expression of the HIV-1 NL4-3 Δ*gag-pol* proviral transgene, adolescent Tg26 transgenics develop a progressive, proliferative renal disease marked by podocyte and tubular epithelial hyperplasia that is indistinguishable both clinically and histopathologically from human HIVAN. In order to determine if cyclin D~1~ plays a role in this hyperplasia, kidneys from three proteinuric 40-day old transgenic siblings and three non-transgenic littermates were stained by immunohistochemistry with antibody to phospho-pRb (Ser780), a site of cyclin D~1~/CDK-4/6 phosphorylation not targeted by cyclin E/CDK-2 complexes that disrupts pRb/E2F binding for G~1~ → S progression \[[@B24]\]. Figure [1](#F1){ref-type="fig"} depicts the intense, heterogeneous nuclear staining of glomerular podocytes and tubular epithelium from hyperplastic nephrons in the diseased transgenics versus the absent staining of nephrons in the non-transgenics consistent with the very low mitotic index in normal kidneys of adult animals \[[@B26]\]. This suggests that cyclin D~1~ is promoting cell-cycle progression during the proliferation of epithelium in diseased kidneys.

![***In situ* immunodetection of phosphorylated serine 780 on pRb in Tg26 kidneys.** Phospho-pRb (Ser780) is not detected in the nuclei of epithelium of normal kidneys (**A**), but is readily detected in podocytes (short arrows) and tubular epithelial cells (long arrows) in hyperplastic nephrons of diseased transgenic kidneys at cortical (**B)**, juxta-medullary (**C**), and medullary (**D**) depths. The prominent staining in many, but not all nuclei, is characteristic of asynchronously proliferating cells. (magnification = 40×)](1471-2180-2-26-1){#F1}

Cyclin D~1~ and phospho-pRb (Ser780) expression in vitro
--------------------------------------------------------

HIV-1 expression in cultured podocytes recapitulates the phenotypic abnormalities induced by HIV-1 expression in infected podocytes *in vivo,* specifically proliferation, loss of contact-mediated growth control, and dedifferentiation \[[@B6]-[@B8]\]. To determine if these phenotypes were marked by enhanced cyclin D~1~ and phospho-pRb (Ser780) expression, we utilized the podocyte cell-culture protocol developed by Rieser et al. \[[@B27],[@B28]\] to study both sub-confluent podocyte growth and podocyte growth during the formation of mature cell-cell contacts at confluence. In this protocol, normal podocytes are growth-arrested 4--5 days after initial confluence and are fully differentiated with mature cell-cell contacts approximately 10 days later. Figure [2A](#F2){ref-type="fig"} shows that cyclin D~1~ message levels are nearly equivalent between mock (\"wild-type\")-, control virus-, and HIV-1-infected subconfluent podocytes, although only the HIV-1-infected subconfluent podocytes had elevated levels of cyclin D~1~ protein. In contrast, cell-cell contact in wild-type and control-infected, but not HIV-1-infected podocytes, caused a severe down-regulation of cyclin D~1~ transcript and protein concomitant with the up-regulation of synaptopodin, a podocyte differentiation marker \[[@B7],[@B28]\], by the end of the 14-day differentiation period. Although HIV-1 infected podocytes showed some decrease in cyclin D~1~ message by the end of the differentiation period, cyclin D~1~ protein levels remained elevated, suggesting activation by HIV-1 of mechanisms that stabilize cyclin D~1~ protein levels. Moreover, HIV-1-infected podocytes, but not control-infected podocytes, had readily detectable phospho-pRb (Ser780) at the end of the differentiation period, suggesting that the stably up-regulated cyclin D~1~ protein remained active in promoting cell-cycle progression (Figure [2B](#F2){ref-type="fig"}). The ongoing proliferation of HIV-1-infected podocytes following cell-cell contact led to the formation of multiple foci (Figure [2C](#F2){ref-type="fig"}) with intense, heterogenous nuclear cyclin D~1~ immunofluorescence consistent with ongoing asynchronous proliferation in this population of cells (Figure [3](#F3){ref-type="fig"}). These data indicate that HIV-1 expression in infected podocytes induces cyclin D~1~ and phospho-pRb (Ser780) expression, hallmarks of cyclin D~1~-mediated G~1~ → S progression. The data, however, do not prove that cyclin D~1~ expression alone is sufficient to cause cell-cycle progression.

![**Expression of cyclin D~1~ and phospho-pRb (Ser780) in HIV-1-infected podocytes.** (**A**) Northern and western blot detection of cyclin D~1~ expression in wild-type, control-infected, and HIV-1-infected podocytes during subconfluent (SC) growth at 33°C and during 14 days of differentiation of confluent podocytes at 37°C shows that neither the cyclin D~1~ transcript nor the elevated cyclin D~1~ protein in HIV-1-infected podocytes (full-length, singly-spliced, and multiply spliced HIV-1 transcripts) are significantly down-regulated by podocyte cell-cell contact or by podocyte differentiation (synaptopodin transcript) when compared to wild-type or control-infected (one transcript from LTR sequences) podocytes. (**B**) Immunodetection of phospho-pRb (Ser780) on several phosphorylated forms (arrows) of pRb in the asynchronously proliferating, HIV-1-infected podocytes that is absent in the quiescent, control-infected podocytes after 14 days of differentiation at 37°C. (**C**) Abundant foci formation in confluent HIV-1-infected podocytes but not in confluent control-infected podocytes due to the ongoing proliferation of HIV-1-infected podocytes after cell-cell contact. Blots are representative of two independent experiments.](1471-2180-2-26-2){#F2}

![**Heterogenous nuclear localization of cyclin D~1~ in HIV-1-infected podocytes.** Immunofluorescent detection of nuclear cyclin D~1~ in quiescent, wild-type podocytes after 14 days of differentiation at 37°C shows light speckled staining in all nuclei (**A**). This differs markedly from the intense nuclear staining of cyclin D~1~ in some, but not all nuclei, of the asynchronously proliferating, HIV-1-infected podocytes (GFP positive podocytes) (**B** and **C**). (magnification = 100×)](1471-2180-2-26-3){#F3}

Requirement of HIV-1 expression for induction of cyclin D~1~
------------------------------------------------------------

We sought to further confirm that HIV-1 expression, and not some idiosyncratic effect of infection, was directly inducing cyclin D~1~ expression in infected podocytes. First, we utilized the small molecule cyclin-dependent kinase inhibitor, flavopiridol, which at low concentrations (e.g., less than 100 nM) can selectively suppress HIV-1 transcript elongation without altering cellular transcripts in cell types of various lineages, including podocytes \[[@B7],[@B29],[@B30]\]. Cyclin D~1~ transcript levels were followed before, during, and after treatment of confluent wild-type or HIV-1 infected podocytes with 50 nM flavopiridol, a dose that suppresses HIV-1 transcription by 70% \[[@B7]\]. Analysis of HIV-1, cyclin D~1~, and glyceraldehyde-3-phosphate dehydrogenase (G3PDH) transcript levels in podocytes treated with flavopiridol for 2 days, followed by drug washout for 1 day, showed that cyclin D~1~ expression paralleled HIV-1 expression in infected podocytes before, during and after suppression of HIV-1 genes (Figure [4](#F4){ref-type="fig"}). Secondly, we utilized single gene mutants of HIV-1 \[[@B8]\] to determine which HIV-1 gene(s) may be involved with up-regulating cyclin D~1~ expression. Analysis of cyclin D~1~ transcript levels in podocytes infected with HIV-1 singly mutated with premature stop codons in the genes encoding the various structural and regulatory proteins of HIV-1 (except *tat*, which is present in every virus) showed that *nef*-deficient virus did not significantly up-regulate cyclin D~1~ expression when compared to the other mutant viruses (Figure [5](#F5){ref-type="fig"}). Taken together, these data indicate that induction of cyclin D~1~ expression requires HIV-1 gene expression and that HIV-1 *nef* is important for this induction.

![**Parallel expression of HIV-1 and cyclin D~1~.** Northern blot de tection of HIV-1, cyclin D~1~, and G3PDH transcripts before (day 14), during (two days with drug, day 16), and after (one day after drug washout, day 17) treatment of wild-type and HIV-1-infected podocytes with 50 nM flavopiridol, a small molecule CDK inhibitor of HIV-1 transcription, showing that cyclin D~1~ expression parallels HIV-1 expression. Blot is representative of two independent experiments.](1471-2180-2-26-4){#F4}

![**Mapping of HIV-1 genes that induce cyclin D~1~ expression.** Northern blot detection of cyclin D~1~ and G3PDH transcripts from wild-type, control-infected, and HIV-1-infected podocytes infected with single gene mutants of HIV-1 (*tat* present in every virus). Similar to wild-type and control-infected podocytes, podocytes infected with *nef*-deficient HIV-1 do not significantly up-regulated cyclin D~1~ expression compared to podocytes infected with other single gene mutant viruses.](1471-2180-2-26-5){#F5}

Discussion
==========

The mechanisms whereby HIV-1 subverts cell-cycle controls in infected renal epithelium have been unclear. Here, we demonstrate that podocytes expressing HIV-1 genes display the hallmarks of cyclin D~1~-dependent cell-cycle progression, specifically, that cyclin D~1~ transcript and protein expression are markedly up-regulated, and that levels of phospho-pRb (Ser780), a target of cyclin D~1~/CDK-4/6 but not cyclin E/CDK-2 complexes \[[@B24]\], are induced *in vitro* and *in vivo.* In addition, preliminary micro-array gene profiling of HIV-1-infected tubular epithelium showed that cyclin D~1~ expression is up-regulated several fold when compared to uninfected tubular epithelium (Michael Ross, personal communication). This suggests that the HIV-1-induced proliferation of infected renal epithelium may be caused by a cyclin D~1~-dependent mechanism, unlike other viruses that bypass a requirement for G~1~-phase cyclins to trigger aberrant cell-cycle progression. Moreover, normal cellular controls on cell-cycle progression appears to be dysregulated by HIV-1 expression because cell-cell contact and differentiation, events that normally lead to the down-regulation of cyclin D~1~ expression \[[@B25]\], did not significantly alter cyclin D~1~ protein levels in HIV-1 infected podocytes. This suggests a novel stabilization of cyclin D~1~ protein in podocytes by HIV-1. We are exploring whether this occurs from enhanced translation of cyclin D~1~ message and/or decreased degradation of cyclin D~1~ protein and whether other D-type cyclins may be involved in phosphorylating pRb in HIVAN.

Prior studies in HIV-1 transgenic animals support the model that HIV-1 gene products interact with endogenous mitogenic pathways in infected renal epithelium. \[[@B11]-[@B14]\]. Kidney transplants between normal and transgenic Tg26 siblings suggested that specific HIV-1 proteins within the kidney, and not circulating factors, transform infected renal epithelium \[[@B13]\]. Indeed, HIV-1 transgenic mice generated with an HIV-1 proviral construct mutated in the Nef \"PXXP\" SH3-binding motif for Src-family kinases failed to develop nephropathy \[[@B31]\], and a recent *in vitro* analysis of podocytes infected with single gene mutants of HIV-1 further suggest that Nef plays a central role in causing the proliferative phenotype in HIVAN \[[@B8]\]. Utilizing these same single gene mutant viruses, we showed here that Nef appears to be play a role in the up-regulation of cyclin D~1~ by HIV-1 *in vitro*. Importantly, these single gene mutants do not exclude the possibility that other HIV-1 gene(s) may cooperate with *nef* to induce cyclin D1, particularly *tat*, which is present in every virus. Cumulatively, however, these observations do suggest a mechanism whereby HIV-1 expression in renal epithelium may induce cyclin D~1~: activation of Src-family kinases by Nef would be expected to up-regulate cyclin D~1~ gene expression and promote the synthesis and stabilization of cyclin D~1~ protein via Src-Ras-MAPK and Src-PI3K-mTOR signal transduction pathways, respectively \[[@B32]-[@B34]\]. Interestingly, our unpublished *in vitro* observations and published data showing marked expression of basic fibroblast growth factor in the interstitium of HIVAN kidneys \[[@B35]\] suggest that soluble mitogens may be important cofactors with HIV-1 expression to induce cyclin D~1~. Thus, interrupting HIV-1 gene expression should down-regulate cyclin D~1~ and correct the phenotypic abnormalities in infected podocytes. In support of this notion, we show here that cyclin D~1~ expression parallels HIV-1 expression before, during, and after suppression of HIV-1 transcription with flavopiridol, and recently, we showed that longer periods of treatment with flavopiridol ameliorate the phenotypic abnormalities of infected podocytes \[[@B7]\].

Conclusions
===========

The following results of this study suggest that HIV-1 expression leads to cyclin D~1~-mediated G~1~ → S progression in infected podocytes: cyclin D~1~ transcript and protein levels are markedly up-regulated, phospho-Rb (Ser780) levels are increased, cyclin D~1~ protein and phospho-Rb (Ser780) levels do not decrease with podocyte cell-cell contact and differentiation, and the up-regulation of cyclin D~1~ requires the expression of HIV-1 genes, particularly HIV-1 *nef.* In sum, these results suggest HIV-induced cell-cycle mechanisms may contribute to aberrant epithelial proliferation in HIVAN.

Methods
=======

Podocyte cell culture and infection
-----------------------------------

Murine podocytes immortalized with interferon-inducible temperature-sensitive SV-40 T antigen (*ts*-SV-40 T) were isolated and infected with replication incompetent GFP-expressing HIV-1 virus, replication incompetent GFP-expressing single-gene mutants of HIV-1, or replication incompetent GFP-expressing control lentivirus containing GFP but no HIV-1 genes as previously described \[[@B7],[@B8]\]. In all cases, 70% to 80% of podocytes showed GFP expression 4 days post infection (data not shown). Podocytes were used before passage twenty and maintained in RPMI 1640 (Life Technologies) supplemented with 10% fetal calf serum, 1 × PenStrep (Life Technologies), and 20 U/ml recombinant interferon-gamma (Life Technologies) at 33°C. Unless otherwise indicated, all studies were conducted at cell confluency and 14 days after inactivation of *ts*-SV-40 T at the non-permissive temperature (37°C) when wild-type podocytes are fully differentiated \[[@B27],[@B28]\].

Immunohistochemistry
--------------------

Kidneys from three 40 day-old Tg26 heterozygous transgenic siblings demonstrating 2+ proteinuria (Chemstrip 2GP, Roche) and three of their non-transgenics littermates were collected in accordance with Animal Use and Care Committee guidelines, fixed (10% buffered formalin), then paraffin-embedded (Department of Pathology, Mount Sinai School of Medicine). Four micron full coronal kidney sections from each animal were adhered to lysine-coated slides and used for immunodetection of phospho-Rb (Ser780) as follows: sections were deparaffinized and hydrated by placing in xylene for 8 minutes, followed by 3 minutes each of 100%, 96%, 80%, 70%, 50%, 30% ethanol, ending with 10 minutes in water; sections then underwent antigen retrieval (Glyca Reagent, Biogenex) followed by immunodetection (Super Sensitive Detection Kit, Biogenex) of phospho-Rb (Ser780) after a 12 hour incubation with a 1:1000 dilution of rabbit anti-phospho-Rb (Ser780) antibody (Cell Signaling) or control rabbit anti-sera (Biogenex) at 4°C.

Immunofluorescence
------------------

Following the 14 day podocyte differentiation protocol on coverslips to establish mature podocytes, wild-type and HIV-1 infected podocytes underwent immunofluorescent detection of cyclin D~1~ as follows: coverslips were washed three times with 1 × PBS, fixed in 60% acetone/3.7% formaldehyde at -20°C for 20 minutes, then washed twice with 1 × PBS; the coverslips where then incubated with a 1:200 dilution of rabbit anti-cyclin D~1~ antibody (Santa Cruz Biotechnology) or control rabbit sera (Biogenex) for 2 hours at room temperature followed by three washes with 1 × PBS; the coverslips were then incubated with a 1:250 dilution of rhodamine-labeled donkey-anti-rabbit anti-sera (Chemicon) for 45 minutes to detect the primary antibody; following three final washes with 1 × PBS, the coverslips were mounted on glass slides using ProLong Antifade (Molecular Probes) for fluorescent detection of GFP and cyclin D~1~ on an Olympus IX70 microscope at 100 × magnification.

Podocyte cell-cell contact
--------------------------

Total RNA and protein were extracted from wild-type, control-infected, and HIV-1 infected podocytes during the Reiser, et al. protocol to study subconfluent podocyte growth and podocyte growth during establishment of mature cell-cell contacts between differentiated podocytes \[[@B27],[@B28]\]. Briefly, RNA and protein were extracted from parallel plates of podocytes using TRIZOL Reagent or RIPA buffer, respectively, under three conditions: 1) during sub-confluent growth at 33°C; 2) immediately upon reaching confluency (day zero); and 3) on day 14 after switching confluent cultures to 37°C. At the end of the differentiation protocol (day 14), additional plates were stained to detect foci formation as follows: cells were washed with 1 × PBS, fixed in methanol for 1 minute, stained with bromophenol blue for 1 minute, then washed again with 1 × PBS. In experiments utilizing the single gene mutant of HIV-1, total RNA was extract from infected podocytes 14 days after switching confluent cultures to 37°C. All experiments were performed twice.

Flavopiridol treatment
----------------------

After the 14-day podocyte differentiation protocol described above, total RNA was extracted from wild-type and HIV-1-infected podocytes before treatment with flavopiridol (Developmental Therapeutics Program, National Cancer Institute) (day 14), two days after suppression of HIV-1 transcription with media containing 50 nM flavopiridol (day 16), and one day after drug washout using media without flavopiridol (day 17). The experiment was performed twice.

Cyclin D~1~ transcript and protein
----------------------------------

RNA and protein samples were analyzed as follows: Podocyte RNA (10 μg) was analyzed by northern blot using probes for HIV-1 *nef-LTR*\[[@B7]\], mouse cyclin D~1~ (cDNA generated by RT-PCR from mouse podocytes and verified by sequence analysis), synaptopodin \[[@B7]\], and G3PDH. Following 7.5% SDS/PAGE, podocyte protein (20 μg) was analyzed by western blot for cyclin D~1~ (ECL detection of a 1:1000 dilution of rabbit anti-cyclin D~1~ antibody, Santa Cruz BioTechnology). Protein (250 μg) from the control-infected or HIV-1-infected podocytes on day 14 of the differentiation protocol was also analyzed by western blot for total pRb (ECL detection of a 1:1000 dilution of rabbit anti-Rb, Santa Cruz Biotechnology) and phospho-Rb (Ser780) (ECL detection of a 1:500 dilution of rabbit anti-phospho-Rb (Ser780) antibody binding, Cell Signaling). Protein concentrations were determined using the Bio-Rad Protein Assay (Bio-Rad Laboratories), and blotting of equivalent amounts of protein was confirmed by transient staining of membranes with Ponceau S solution (0.5% Ponceau S/1% acetic acid) and by western blot for β-actin (Chemicon). Signal intensity was calculated using the UN-SCAN-IT gel v4.3 (Silk Scientific).
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